MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

psilocybin

  • Home
  • psilocybin
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial
Posted innews Psychiatry

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial

Posted by By MedXY 05/19/2026
Psilocybin-assisted psychotherapy showed promising but inconclusive antidepressant effects in treatment-resistant depression, with notable acute adverse events and safety concerns.
Read More
Psychedelics Target Neuroimmune Interactions to Limit Fear
Posted inAllergy & Immunology Clinical Updates Neurology news Specialties

Psychedelics Target Neuroimmune Interactions to Limit Fear

Posted by By MedXY 08/05/2025
Research reveals how psychedelics modulate immune-to-brain communication to reduce fear, offering new therapeutic avenues for stress-related psychiatric disorders.
Read More
  • Distinct Molecular and Clinical Profiles of USH2A-Associated Retinitis Pigmentosa in Korean Patients: Implications for Targeted Therapy
  • Cystoid Macular Edema Following Cultured Human Corneal Endothelial Cell Injection: Incidence, Risk Factors, and Visual Prognosis
  • Post-Tonsillectomy Hemorrhage in Lebanon: Prevalence, Risks, and Implications for Adult Patients
  • Beta-Trace Protein Quantification: A Novel Diagnostic Tool for Early Detection of CSF Leak Post-Endoscopic Endonasal Sellar Tumor Surgery
  • Colovac Device vs Diverting Loop Ileostomy: A Prospective Pooled Analysis in Rectal Cancer Surgery
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation ischemic stroke MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top